Comparative Efficacy and Safety of Three CDK4/6 Inhibitors in Combination With Endocrine Therapies in Patients With HR+/HER2− Metastatic or Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
BMC Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 - metastatic or advanced breast cancer patients: a network meta-analysis
BMC Cancer 2023 Aug 31;23(1)816, Y Liu, J Wu, Z Ji, L Chen, J Zou, J Zheng, W Lin, J Cai, Y Chen, D Zheng, Y Chen, Z LiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.